Apheresis Articles & Analysis: Older
6 news found
The collection, processing, and shipment of fresh apheresis material must therefore by rigorously controlled to ensure optimal cell quality and performance for the patient or downstream application. ...
The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluation. ...
Most AEs reported in the screening, mobilization, apheresis and conditioning periods were SCD-related events. One serious adverse event of sickle cell anemia with crisis (vaso-occlusive crisis or VOC) was reported approximately nine months after treatment with SAR445136 in one patient, and no other SCD-related events were reported in the four patients post-infusion. ...
Most AEs reported in the screening, mobilization, apheresis and conditioning periods were SCD-related events. One serious adverse event of sickle cell anemia with crisis (vaso-occlusive crisis or VOC) was reported approximately nine months after treatment with SAR445136 in one patient, and no other SCD-related events were reported in the four patients post-infusion. ...
” Addition of AKTi during manufacturing results in improved phenotype and proliferative potential of SPEAR T-cells – attributes that may contribute to more sustained antitumor immune responses In vitro analyses of manufactured product samples ADP-A2M4CD8 SPEAR T-cells were manufactured with and without AKTi Samples manufactured with AKTi expanded more effectively during ...
Both French companies are renomated experts in the market of hemodialysis and apheresis for dialysis centres and hospitals. Hemotech & Hema T. Medical deliver high quality medical devices intended to dialysis and apheresis. Hemotech was founded back in 1988 with 2 activities: dialysis and transfusion. ...